About Conference

Organizing successful conferences has been at the core of Conference Series llc LTD. We are delighted to organize the 23^rd World Congress on Toxicology and Pharmacology during June 22-23, 2021 at Kyoto, Japan.

Conference Series llc LTD organizes a series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why Toxicology Congress 2021??

At Toxicology Congress 2021 you can meet the world leading toxicologists, pharmacologists, clinical research professionals, biochemists and also the industrialists who will provide you with the latest innovations and scientific approaches thus help you in widening your scientific knowledge.

The topics of the Congress will reflect the recent advances, current trends, future trends and new approaches in Toxicology and Pharmacology.  The congress will cover among others:  Mechanisms and modes of action of various toxins, Clinical and Forensic toxicology, Emerging in vitro models, Medicine Development and Safety Testing, Regulatory toxicology and last but not least, a broad scope of pharmacology and toxicology in different fields.

Thus, our objective is, to create platforms which will gather eminent scientists who will undoubtedly enrich our congress during the Q&A sections.

Major Associations around the Globe:

• Society of Toxicology, USA (SOT)
• Society of Toxicology of Canada
• Latin American Association of Toxicology (ALATOX)
• Japanese Society of Toxicology
• Italian Society of Toxicology
• German Society of Toxicology
• EUROTOX
• British Toxicology Society
• French Society of Toxicology
• International Society of Regulatory Toxicology and Pharmacology

Target Audience:

• Professors
• PhD Scholars
• Students carrying out laboratory and field studies
• Pharmaceutical Industrial Giants
• Toxicology Societies and the people Associated
• Noble laureates in Health Care and Medicine
• Pharmacists
• Genetic Professionals
• Forensic Professionals
• Toxicology Professionals
• Pathology Professionals
• Clinical Laboratories and Technicians 
• Bio instruments Professionals
• Bio-informatics Professionals
• Software development companies
• Research Institutes and members
• Supply Chain companies
• Manufacturing Companies
• Training Institutes
• Business Entrepreneurs

Market Analysis

Increasing demand to curb drug toxicity at the drug development phase coupled with new drug development is expected to fuel growth of ADME toxicology testing market over the forecast period. ADME testing refers to the pharmacokinetic testing of a compound in living organism and known as ADME/Tox. Drug development is a cost and time intensive process. The traditional drug development process includes toxicity and efficacy testing in in-vivo environment which is responsible for late stage failure of drugs in human body, as the results observed in animal models and human are different. To overcome this drug failure hurdle drug manufacturers are incorporating ADME toxicity testing in early drug developmental phases.  Increasing adoption of ADME toxicity testing as cost and time curbing tool is further expected to drive growth of this market. Introduction of technologically advanced computer based testing models are additionally fuelling growth of this market.

ADME toxicity testing market is studied with respect to in-vitro and in-vivo technologies. In-vitro technologies are expected to register lucrative growth owing to increasing ethical concerns over animal use in clinical trials. Insilico technologies of in-vivo testing are gaining popularity due to its capability of effective cost reduction due to early ADME toxicology prediction. Use of ADME toxicity computer modeling is expected to rise because of associated benefits related to increase throughput screening.

Glance at the Market:

The in vitro toxicology testing market is expected to reach USD 8.74 Billion by 2022 from an estimated USD 6.34 Billion in 2017, at a CAGR of 6.6%. The key factors driving the growth of this market include opposition to animal testing, growing demand for in vitro technology in the European market, new and promising technologies, and increasing R&D expenditure to detect toxicity at an early stage.

Based on toxicity endpoints and tests of in vitro toxicology testing, the market is subsegmented into ADME, genotoxicity, skin irritation and sensitization, cytotoxicity, ocular toxicity, organ toxicity, phototoxicity, dermal toxicity, and other toxicities like eco toxicity, endocrine disruption, and reproductive & developmental toxicity. In 2017, the ADME segment is expected to account for the largest share of the global in vitro toxicology testing market owing to its highly reproducible & accurate data and the increasing demand to curb drug toxicity at the drug development phase.

The major players in the global in vitro toxicology testing market include Cyprotex, Covance, Eurofins Scientific SE, GE Healthcare, Thermo Fisher Scientific, SGS SA, Promega Corporation, Merck KGaA, Charles River Laboratories, Inc., and Lonza Group Ltd., among others.

Scientific sessions

Track 1: Toxicology

Track 2: Toxicology and Risk Assessment

Track 3: Analytical Toxicology

Track 4: Genotoxicity

Track 5: Forensic Toxicology

Track 6: Food Safety and Environmental Toxicology

Track 7: Toxicology Applications

Track 8: Experimental and Toxicologic Pathology

Track 9: Medical and Clinical Toxicology

Track 10: Industrial & Occupational Toxicology

Track 11: Toxicology Testing

Track 12: Pharmacology

Track 13: Applied Pharmacology

Track 14: Pharmacological Testing

Track 15: Cardiovascular Pharmacology

Track 16: Medicine Development and Safety Testing

Past Conference Report

Toxicology Congress 2020

Past Reports  Gallery  

Toxicology Congress 2019

Past Reports  Gallery  

Toxicology Congress 2018

Past Reports  Gallery  

Toxicology Congress 2017

Past Reports  Gallery